Rheumatoid arthritis and COVID-19: Three years later

During the three years that have passed since the beginning of the COVID-19 pandemic, many new fundamental and medical problems have been discovered regarding the relationship between the viral infection and many common chronic non- infectious diseases. Among the latter, an important position is occupied by immuno-inflammatory rheumatic diseases (IIRD), which include rheumatoid arthritis (RA). To date, there is no doubt that patients with RA are at risk for SARS-CoV-2 infection, a severe course of infection that necessitates hospitalization and death. The article presents current data on the course and outcomes of COVID-19 in patients with RA. The literature and own data on postcovid syndrome in this group of patients are presented. The necessity of vaccination against SARS-CoV-2 in patients with IIRD, including those with RA, was substantiated. The prospects for further study of the features of COVID-19 in patients with RA are outlined.

[1]  P. Raghav,et al.  Potential treatments of COVID-19: Drug repurposing and therapeutic interventions , 2023, Journal of Pharmacological Sciences.

[2]  A. Skapenko,et al.  COVID-19 vaccination in individuals with inflammatory rheumatic diseases , 2022, Nature Reviews Rheumatology.

[3]  T. Bergquist,et al.  Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C) , 2022, Seminars in Arthritis and Rheumatism.

[4]  Andrew T. Kroger,et al.  American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5 , 2022, Arthritis & rheumatology.

[5]  J. Sparks,et al.  Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study , 2022, Seminars in Arthritis and Rheumatism.

[6]  J. Sparks,et al.  Risk of COVID‐19 among unvaccinated and vaccinated patients with rheumatoid arthritis: a general population study , 2022, Arthritis care & research.

[7]  N. Muravyeva,et al.  Immunogenicity of Vaccines Against SARS-CoV-2 In Patients With Rheumatic Diseases , 2022, Antibiotics and Chemotherapy.

[8]  R. Xavier,et al.  Update to “guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force” , 2022, Advances in Rheumatology.

[9]  A. Eftekharsadat,et al.  Autoimmune inflammatory rheumatic diseases post-COVID‐19 vaccination , 2022, International Immunopharmacology.

[10]  M. Kudo,et al.  Case Report: New-Onset Rheumatoid Arthritis Following COVID-19 Vaccination , 2022, Frontiers in Immunology.

[11]  J. Sparks,et al.  DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study , 2022, Seminars in Arthritis and Rheumatism.

[12]  C. Torp‐Pedersen,et al.  COVID-19 infection and hospitalisation risk according to vaccination status and DMARD treatment in patients with rheumatoid arthritis , 2022, Rheumatology.

[13]  Matthew D. Li,et al.  Assessing the Severity of COVID‐19 Lung Injury in Rheumatic Diseases versus the General Population Using Deep Learning‐Derived Chest Radiograph Scores , 2022, Arthritis care & research.

[14]  P. Sfikakis,et al.  Different COVID-19 outcomes among systemic rheumatic diseases: a nation-wide cohort study , 2022, medRxiv.

[15]  M. Merad,et al.  The immunology and immunopathology of COVID-19 , 2022, Science.

[16]  A. Lila,et al.  Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues , 2022, Rheumatology Science and Practice.

[17]  M. Merad,et al.  Pathological sequelae of long-haul COVID , 2022, Nature Immunology.

[18]  J. Sparks,et al.  Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy , 2022, RMD Open.

[19]  M. Netea,et al.  A guide to immunotherapy for COVID-19 , 2022, Nature Medicine.

[20]  D. Ye,et al.  New‐onset autoimmune phenomena post‐COVID‐19 vaccination , 2021, Immunology.

[21]  A. Lila,et al.  Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review , 2021, Rheumatology Science and Practice.

[22]  C. Zeng,et al.  Increased Risk of COVID‐19 in Patients With Rheumatoid Arthritis: A General Population‐Based Cohort Study , 2021, Arthritis care & research.

[23]  M. Konig,et al.  SARS–CoV‐2 Infection and COVID‐19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta‐Analysis , 2021, Arthritis & rheumatology.

[24]  Andreas Krause,et al.  TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD , 2021, RMD Open.

[25]  L. Trupin,et al.  Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19 , 2021, JAMA network open.

[26]  E. Nasonov,et al.  B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19) , 2021, Rheumatology Science and Practice.

[27]  C. Kavadichanda,et al.  Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States , 2021, Seminars in Arthritis and Rheumatism.

[28]  J. Yazdany,et al.  Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry” by Sparks et al , 2021, Annals of the Rheumatic Diseases.

[29]  A. Baranov,et al.  Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia , 2021, Rheumatology Science and Practice.

[30]  J. G. Ryan,et al.  Predictors of hospitalization in patients with rheumatic disease and COVID-19 in Ireland: data from the COVID-19 global rheumatology alliance registry , 2021, Rheumatology advances in practice.

[31]  K. Michaud,et al.  Risk of COVID‐19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At‐Risk Individuals , 2021, Arthritis & rheumatology.

[32]  David A. Drew,et al.  Attributes and predictors of long COVID , 2021, Nature Medicine.

[33]  Jianbo Liu,et al.  Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis , 2021, Rheumatology International.

[34]  E. Nasonov Coronavirus disease 2019 (COVID-19) and autoimmunity , 2021, Rheumatology Science and Practice.

[35]  M. Gianfrancesco,et al.  Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’’ by Mulhearn et al , 2021, Annals of the Rheumatic Diseases.

[36]  C. Turesson,et al.  Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study , 2021, Annals of the Rheumatic Diseases.

[37]  Anonymous Correction: High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV brasil registry , 2021, RMD Open.

[38]  S. Villapol,et al.  More than 50 long-term effects of COVID-19: a systematic review and meta-analysis , 2021, Scientific Reports.

[39]  P. Brodin Immune determinants of COVID-19 disease presentation and severity , 2021, Nature Medicine.

[40]  H. Lorenz,et al.  Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases , 2021, RMD Open.

[41]  C. Torp‐Pedersen,et al.  Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark , 2020, Rheumatology.

[42]  Hyon K. Choi,et al.  COVID‐19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study , 2020, Arthritis & rheumatology.

[43]  Florence Nassim Jean-David Didier Yannick Blanca Zahir Emma Aeschlimann Ait-Abdallah Albert Alcais A Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients , 2020, Annals of the Rheumatic Diseases.

[44]  E. Nasonov,et al.  Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity , 2020, Rheumatology Science and Practice.

[45]  E. Nasonov,et al.  The role of Interleukin 6 inhibitors in therapy of severe COVID-19 , 2020, Biomedicine & Pharmacotherapy.

[46]  A. Ogdie,et al.  COVID‐19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease‐Modifying Antirheumatic Drugs on Clinical Outcomes , 2020, Arthritis & rheumatology.

[47]  K. Bhaskaran,et al.  OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.

[48]  L. Trupin,et al.  Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2020, Annals of the Rheumatic Diseases.

[49]  Евгений Львович Насонов Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога , 2020 .

[50]  Georg Schett,et al.  COVID-19: risk for cytokine targeting in chronic inflammatory diseases? , 2020, Nature Reviews Immunology.

[51]  P. Lipsky,et al.  Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases , 2019, Nature Reviews Rheumatology.

[52]  W. Dixon,et al.  Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative , 2016, Annals of the rheumatic diseases.

[53]  OUP accepted manuscript , 2021, Rheumatology.